Authors

Andrea Richardson, MD, PhD, Sibley Memorial Hospital

Latest:

The Applications of a Mixed Reality Laboratory

Andrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.

Andrea V. Barrio, MD, FACS

Latest:

Dr. Barrio on Neoadjuvant Chemo to De-Escalate Axillary Node Dissection in Breast Cancer

Andrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.

Andrea Wang-Gillam, MD, PhD

Latest:

Dr. Wang-Gillam on Next Steps With Defactinib Combo in Pancreatic Ductal Adenocarcinoma

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Andrea Wang-Gilliam, MD, PhD, Washington University

Andreas du Bois, MD

Latest:

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Andreas du Bois, MD, PhD

Latest:

Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian Cancer

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.

Andreas Hochhaus, MD

Latest:

Dr. Hochhaus on TFS With Nilotinib in Patients With CML

Andreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).

Andreas Kaubisch, MD

Latest:

Dr. Kaubisch on the REACH Trials in HCC

Andreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.

Andrei R. Shustov, MD, SCCA

Andres Poveda, MD

Latest:

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer

Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

Andrew A. Lane, MD, PhD

Latest:

Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future Potential

Dr. Andrew Lane discusses CD123-targeted therapies, particularly the antibody-drug conjugate pivekimab sunirine (PVEK), for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). He notes PVEK's promising response rates and safety profile from early trial data, including lower risk of concerning side effects like capillary leak syndrome that can occur with the currently approved CD123-targeting agent tagraxofusp. In closing, he emphasizes accurately diagnosing BPDCN via expert hematopathology review and referral to specialized centers taking a cross-disciplinary approach, as combining emerging CD123-directed therapies with stem cell transplant as appropriate gives the best chance for optimal BPDCN management.

Andrew Branagan, MD

Latest:

Dr. Branagan on Novel Induction Therapies With Transplant in Myeloma

Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

Andrew Brenner, MD, PhD

Latest:

Liposomal Encapsulation of Radiotherapeutics Holds Promise in Treating Glioblastoma

Andrew Brenner, MD, PhD, discusses how liposomal encapsulation of radiotherapeutics holds significant promise as a treatment of glioblastoma.

Andrew D. Seidman, MD

Latest:

Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center

Latest:

Future Directions for the Management of HR+ Breast Cancer

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

Andrew D. Smith

Latest:

Melanoma Expert Focuses on Finding the Next Best Therapy

Clinical trials demand extreme rigor. A mistake in trial design, like a bookkeeping error, can lead regulators to reject a potentially valuable drug. Many researchers dislike this intense focus on dotting i’s and crossing t’s. Omid Hamid, MD, enjoys the challenge.

Andrew D. Zelenetz, MD, PhD

Latest:

Dr. Zelenetz on Progress Made in MCL Treatment

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Andrew Dannenberg, MD

Latest:

Dr. Dannenberg on Inflammation and Increased Breast Cancer Risk

Andrew Dannenberg, MD, professor of Medicine, Weill Cornell Medical College, discusses the association between breast inflammation and breast cancer risk.

Andrew E. Hendifar, MD

Latest:

Dr. Hendifar Discusses the Future Treatment of NETs

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the future treatment landscape for patients with neuroendocrine tumors (NETs).